Trial Profile
A Double-Blind Randomized Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple 1200 mg Dose Intravenous Oritavancin Infusions in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Dec 2023
Price :
$35
*
At a glance
- Drugs Oritavancin (Primary)
- Indications Bacteraemia; Skin and soft tissue infections
- Focus Adverse reactions
- Sponsors Melinta Therapeutics; The Medicines Company
- 25 Oct 2016 Status changed from active, no longer recruiting to completed.
- 20 Jul 2015 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov
- 15 Jun 2015 New trial record